Calyx AI Strengths, Domain Expertise, and Key Differentiators
In January 2021, Parexel completed the separation of its Parexel Informatics and Medical Imaging business. The strategic move is designed to simplify and streamline Parexel’s business strategy and customer relationships while best positioning both organizations for continued, long-term growth and success. As part of the separation, Parexel Informatics will become Calyx.
Calyx is investing in innovative technology, serving new markets, and delivering more value to help the global bio-pharmaceutical industry bring much-needed treatments to patients, faster.
Parexel will continue to leverage Calyx’s Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), Interactive Response Technology (IRT) and Regulatory Information Management (RIM) solutions moving forward as part of the company’s clinical development offerings. Calyx will be privately held by the same ownership group that has owned Parexel since 2017.
Calyx will be led by Chief Executive Officer Gavin Nichols and the company will be headquartered in Nottingham, United Kingdom, and Durham, North Carolina. The new organization will employ approximately 2,300 employees.
Calyx AI Recent Developments
In May 2021, Calyx published the availability of Calyx RIM v7.0 for its industry-leading Regulatory Information Management (RIM) system. The RIM v7.0 release represents Calyx’s first update that leverages Microsoft’s cloud-based, Azure native technology. With tailored, direct delivery based on clients business needs and schedules, Calyx RIM on Azure ensures minimal system disruption, which enables clients to access new system features while maintaining patient safety and compliance with global regulatory requirements.
In April 2021, Calyx declared the availability of Calyx CTMS v15.0, an advanced clinical trial management system for reducing risk and improving efficiencies in clinical development. Calyx CTMS on Microsoft’s Azure cloud technology delivers robust features that simplify the oversight of clinical trial operations, improve data quality, and reduce trial timelines and cost.
Calyx AI Customers in ARTW Customer Database
Leveraging a rigorous data-centric research methodology, APPS RUN THE WORLD asks the simple question: Who’s buying Calyx AI applications and why? And we provide the answers – supported by decades of research – to our clients around the world. Our Customer database has over 100 data fields that detail company usage of Calyx AI and other enterprise apps by function, customer size, industry, location, implementation status, partner involvement, Line of Business Key Stakeholders and IT decision makers contact details. List of Verified Calyx Medical Imaging, Calyx CTMS,Calyx IRT, Calyx EDC, Calyx RIM customers.
Calyx AI Overview
Ownership: - Pamplona Capital Management
Number of Employees: 2300
Functional Markets: ERP Services and Operations,
Key Verticals: Life Sciences,
Calyx AI Key Enterprise and Cloud Applications
Calyx Medical Imaging, Calyx CTMS,Calyx IRT, Calyx EDC, Calyx RIM
Calyx AI Revenues, $M:
|Type/Year||2019||2020||YoY Growth, %|
|Total Revenues, $M||Subscribe||Subscribe||Subscribe|
|Enterprise Applications Revenues, $M||Subscribe||Subscribe||Subscribe|
|Cloud Applications Revenues, $M||Subscribe||Subscribe||Subscribe|
* Enterprise Applications Revenues = License + Support & Maintenance + SaaS
** All revenue figures are estimates based on public records, Cloud and Non-Cloud business models in Apps Run The World's vendor database, and annual survey results including vendor feedback.
Calyx AI Revenue Breakdown By Type, $M:
|Type||License||Prof. Services||Hardware||Support & Maintenance||SaaS||PaaS||IaaS||Other (Non Enterprise Application Revenues)||Total|
|% of Total Revenues||Subscribe||Subscribe||Subscribe||Subscribe||Subscribe||Subscribe||Subscribe||Subscribe||100%|
Calyx AI Enterprise Applications Revenues By Functional Markets, $M:
Calyx AI Enterprise Applications Revenues By Verticals, $M:
Calyx AI Revenues By Region, $M
|Region||% of Total Revenues||2020 Total Revenues, $M||2020 Enterprise Applications Revenues, $M||2020 Cloud Applications Revenues, $M|
Calyx AI Direct vs Indirect sales
|Region||Direct Sales||Indirect Sales||Total|
Calyx AI Customers - Breakdown by Geo, Size, Vertical and Product
No. of Calyx AI Customers: 300
No. of Calyx AI Enterprise Applications Customers: x
No. of Calyx AI Cloud Customers: x
No. of Calyx AI Cloud Subscribers: x
Calyx, provider of Medical Imaging, eClinical, and Regulatory solutions and services to solve complex challenges in clinical research started as an independent company following the strategic separation of the Parexel Informatics business from Parexel International. With 250 new drug approvals in its history, Calyx has supported over 25,000 trials involving more than fourteen million patients. The company will continue its focus on providing innovative technology solutions and services to speed the discovery of new treatments.
Calyx AI Market Opportunities, M&A and Geo Expansions
Calyx RIM on Azure combines Calyx’s industry leading expertise in global regulatory compliance with the power and capabilities of Microsoft’s scalable, flexible, and secure global cloud platform. The alliance ignites Calyx’s ability to lead the digital transformation of the life sciences industry.
In February 2021, the Calyx eClinical solutions and services provider most relied on for solving complex data challenges in clinical research, today published a scientific consulting program aimed at optimizing imaging processes and outcomes to accelerate the clinical development of new medical treatments. Through Calyx Scientific Consulting, biopharmaceutical researchers can extend the deep and diverse experience of Calyx’s highly tenured scientific, medical, and regulatory experts to their own clinical development teams.
Calyx AI Risks and Challenges
Consolidation among the big pharmas could impact long-term growth for the new company Calyxl.
In August 2021, Craig M. Mooney has joined Calyx as Vice President of Scientific E-tech Enabled Services. Mooney has nearly 30 years of experience in the clinical development industry, with a concentrated focus on optimizing IRT to improve clinical trial efficiencies.
In May 2021, Calyx declared that Catalyst Clinical Research will enter into a partnership with Calyx to leverage Calyx’s Medical Imaging solution for their customers’ oncology trials. A leading provider of clinical research services, Catalyst Clinical Research’s full-service, niche oncology CRO solution is focused on next-generation cancer therapies. Catalyst Oncology offers skilled management of immuno-oncology and targeted therapies, as well as expert oversight of complex study designs to deliver customized clinical research solutions exclusively for the biotech market.
In February 2021, Calyx made an expansion to its Executive Leadership Team, appointing Dr. Stephen M. Bravo as its Chief Medical Officer (CMO). As CMO, Dr. Bravo will lead the company’s scientific, medical, and clinical groups in evolving the Calyx reader model and in defining solutions and services that meet the needs of Calyx customers today and in the field of clinical research continues to evolve.
In February 2021, Calyx expanded to its Executive Leadership Team. Richard Wallace joins Calyx as Chief Digital and Information Officer (CDIO). As CDIO, Richard is responsible for delivering and leading a robust, scalable, and high-performing product technology organization at Calyx.
Calyx AI Ecosystem, Partners, Resellers and SI
Calyx has two corporate headquarters in Nottingham, the UK and North Carolina, the US. Also has offices worldwide such as Shanghai and Beijing in China, Orleans in France, Hyderabad, in India, Ingolstadt and Berlin in Germany, another office in the USA in Boston, and Tokyo, Japan.
In July 2021, Calyx expanded its presence with the opening of its US headquarters in Morrisville, North Carolina. Adjacent to Research Triangle Park (RTP), the facility was selected for its proximity to many of Calyx’s clients, including some of the industry’s largest pharmaceutical companies and clinical research organizations (CROs).
In January 2021, Calyx made a partnership program for Clinical Research Organizations (CROs). The program, “ACTIVATE Solutions for CRO Partners,” is designed to provide close alignment between Calyx and its CRO partners. By participating in the ACTIVATE program, CROs can meet the needs of their many different clients and help accelerate trial execution and data collection, ultimately delivering more customer value.
Calyx AI Cloud Infrastructure Insights
Subscribe to read more about:
- Calyx AI Public Cloud and Infrastructure (IaaS)
- Calyx AI Platform (PaaS)
- Calyx AI Application Delivery
- Calyx AI Private Cloud and Data Centers
Data used in research reports are derived from publicly available documents, continuous surveys of applications vendors, customers, resellers, Independent Software Vendors, systems integrators and other verifiable sources.
Vendor shares and market forecast results are based on a combination of existing databases as well as demand side and supply side research conducted throughout the year with validation from vendors, customers, channel partners and documentations such as earnings releases and 10Q and 10K filings, vertical industry studies, regional and country-level statistics from public and private institutions(i.e. colleges, universities, government agencies and trade associations).
For additional information on our methodologies, here's the link:https://www.appsruntheworld.com/About Us
Copyright © 2022, APPS RUN THE WORLD